Clinical trials: Multiple Myeloma at First Relapse
Multiple Myeloma, Hematological Neoplasms
ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
The primary aim of this observational study is to collect safety and effectiveness data for bortezomib used at first relapse in a group of multiple myeloma patients who received specific and well defined first line treatments…
- Trial name
- NCT00440479
- Testing
- Bortezomib
- Where
- 9 sites in Netherlands
- Volunteers
- 11 people
- Sponsor
- Janssen-Cilag B.V.